Effects of statins on mitochondrial pathways

Many patients who stop statins do so over muscle aches. This review goes looking for a biological explanation, in the cell’s power plants — the mitochondria.

The authors assemble the mechanisms by which statins might disturb mitochondrial function: depleting coenzyme Q10 (whose synthesis the statin pathway can reduce), interfering with the respiratory chain, disrupting calcium handling, and raising oxidative stress. They connect these to the cluster of statin-associated complaints — muscle symptoms, a small diabetes risk, and cognitive concerns.

The practical takeaway is nuance, not alarm: understanding a plausible mechanism for statin side effects can help identify susceptible patients and rationalize mitigation strategies such as CoQ10 supplementation, without abandoning a drug class of proven benefit.

We rate the evidence moderate: a deep, 160-reference review spanning experimental and clinical work, critically assessed, though some authors carry conflicts and it is narrative rather than systematic. Its clinical significance is moderate — mechanistic insight relevant to managing real-world tolerability for the millions on statins. Read it alongside the large randomized evidence (Collins et al.) showing most reported muscle symptoms are nocebo: this review describes a real biological pathway without overturning the conclusion that statins’ benefits dominate for appropriate patients.